Figure 2
Figure 2. p53 mRNA is stabilized in JEKO-1 after NMD inhibition. (A) p53 mRNA levels were analyzed by real-time PCR in nontreated cells (0) and after emetine (E) or emetine plus actinomycin D treatment during a time course (A1, A3, A5 and A7) in JEKO-1 (▩) and REC-1 (■). The expression levels were related to mock-treated cells (0). (B) After microarray normalization, the signals obtained with the GCOS software for p53 were log2 transformed and plotted for mock-treated (□), emetine-treated (▩), and emetine plus actinomycin D–treated (■) cells. (C) The p53 IRs for each cell line were plotted together with the p53 SR in JEKO-1 for both treatments, emetine (▩) and emetine plus actinomycin D (■).

p53 mRNA is stabilized in JEKO-1 after NMD inhibition. (A) p53 mRNA levels were analyzed by real-time PCR in nontreated cells (0) and after emetine (E) or emetine plus actinomycin D treatment during a time course (A1, A3, A5 and A7) in JEKO-1 (▩) and REC-1 (■). The expression levels were related to mock-treated cells (0). (B) After microarray normalization, the signals obtained with the GCOS software for p53 were log2 transformed and plotted for mock-treated (□), emetine-treated (▩), and emetine plus actinomycin D–treated (■) cells. (C) The p53 IRs for each cell line were plotted together with the p53 SR in JEKO-1 for both treatments, emetine (▩) and emetine plus actinomycin D (■).

Close Modal

or Create an Account

Close Modal
Close Modal